# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	ABN 15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christine BARTLETT
Date of last notice	06/07/2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest	
(including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	30/09/2021
No. of securities held prior to change	159,223
	Direct – 159,223
Class	FPO
Number acquired	9,098
Number disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	\$5,640.76
No. of securities held after change	168,321
	Direct- 168,321

<sup>+</sup> See chapter 19 for defined terms.

Nature of change	Shares purchased under NED's Share Plan
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

### Part 3 – +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was	
this provided?	

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	ABN 15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Gerald MANUEL
Date of last notice	06/07/2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest		
(including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.		
Date of change	30/09/2021	
No. of securities held prior to change	<b>328,001</b> Direct – 328,001	
Class	FPO	
Number acquired	9,389	
Number disposed	7,007	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	\$5,821.18	
No. of securities held after change	<b>337,390</b> Direct – 337,390	

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3Y Change of Director's Interest Notice

Nature of change	Shares purchased under NED's Share Plan
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

### Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	ABN 15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Kathryn SPARGO
Date of last notice	06/07/2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest	Self-managed superannuation fund of	
(including registered holder)	Director Spargo Super Pty Ltd (atf Spargo	
Note: Provide details of the circumstances giving rise to the relevant interest.	Super Fund)	
Date of change	30/09/2021	
No. of securities held prior to change	272,087	
	Direct - 152,087	
	Indirect – 120,000	
Class	FPO	
Number acquired	8,230	
Number disposed		
Value/Consideration	\$5,102.60	
Note: If consideration is non-cash, provide details and estimated valuation		
No. of securities held after change	280,317	
	Direct - 160,317	
	Indirect – 120,000	

<sup>+</sup> See chapter 19 for defined terms.

Nature of change	Shares purchased under NED's Share Plan
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

### Part 3 – \*Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the	
trade to proceed during this period?	
If prior written clearance was provided, on what date was	
this provided?	

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	ABN 15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael SAMMELLS
Date of last notice	06/07/2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest	
(including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	30/09/2021
No. of securities held prior to change	52,876
	Direct - 52,876
Class	FPO
Number acquired	9,678
Number disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	\$6,000.36
No. of securities held after change	68,554
	Direct- 68,554

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3Y Change of Director's Interest Notice

Nature of change	Shares purchased under NED's Share Plan
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

### Part 3 – +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	ABN 15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Raymond Mark GUNSTON
Date of last notice	06/07/2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest		
(including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.		
Date of change	30/09/2021	
No. of securities held prior to change	589,109	
	Direct - 589,109	
Class	FPO	
Number acquired	17,109	
Number disposed		
Value/Consideration	\$10,607.58	
Note: If consideration is non-cash, provide details and estimated valuation		
No. of securities held after change	606,218	
	Direct - 606,218	

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3Y Change of Director's Interest Notice

Nature of change	Shares purchased under NED's Share Plan
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

### Part 3 – +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a <sup>+</sup> closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was	
this provided?	

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.